Beyond Next Aims To Boost Bioventures Over Japan Hurdles
Set up to support the development of bioventures in Japan, Tokyo’s Beyond Next Ventures sees itself as a broad-benefit accelerator able to work with a wide range of partners to help discover and develop life science innovation, in an environment that still presents challenges.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.